<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795145</url>
  </required_header>
  <id_info>
    <org_study_id>A5951151</org_study_id>
    <nct_id>NCT00795145</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Effect Of Linezolid On QTc Interval</brief_title>
  <official_title>Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FDA has asked Pfizer to assess the risk of linezolid on QT interval (obtained from ECG
      readings) which could predispose patients to ventricular arrhythmias. This study is conducted
      to satisfy this requirement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From the time the subject had taken at least one dose of study treatment up to 5 weeks</time_frame>
    <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Mean Time-Matched Difference in Time Corresponding to Beginning of Depolarization to Repolarization of the Ventricles, Corrected for Heart Rate Using Fridericia's Formula (QTcF Interval) Between Linezolid 600 mg and 1200 mg Compared to Placebo</measure>
    <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
    <description>The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for ventricular rate (VR) using the QT and VR from each electrocardiogram by Fridericia's formula (QTcF = QT divided by cube root of VR in seconds). A measure of dispersion is not available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf) and Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC Last)</measure>
    <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
    <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Clearance of Linezolid (CL)</measure>
    <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
    <description>Drug clearance = Dose / AUC inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Steady-State Volume of Distribution (Vss)</measure>
    <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
    <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin and Placebo</measure>
    <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
    <description>A measure of dispersion is not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Mean Time-Matched Difference in Uncorrected QT Intervals Between Linezolid 600 mg and 1200 mg Compared to Placebo</measure>
    <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
    <description>A measure of dispersion is not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: AUC Inf and AUC Last</measure>
    <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
    <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Cmax</measure>
    <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Tmax and t1/2</measure>
    <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Tmax is the time to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: CL</measure>
    <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
    <description>Drug clearance = Dose / AUC inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Vss</measure>
    <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
    <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Number of Subjects With AEs and SAEs</measure>
    <time_frame>From the time the subject had taken at least one dose of study treatment up to 5 weeks</time_frame>
    <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: 900 mg linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: 1200 mg linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 600 mg linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 1200 mg linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 400 mg Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous, Placebo control for blinding, Normal Saline, Single dose</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 900 mg</intervention_name>
    <description>Intravenous, 900 mg linezolid, single dose</description>
    <arm_group_label>Cohort 1: 900 mg linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 1200 mg</intervention_name>
    <description>Intravenous, 1200 mg linezolid, single dose</description>
    <arm_group_label>Cohort 1: 1200 mg linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous, Placebo control for blinding, Normal Saline, Single dose</description>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 600 mg</intervention_name>
    <description>Intravenous, 600 mg linezolid, single dose</description>
    <arm_group_label>Cohort 2: 600 mg linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 1200 mg</intervention_name>
    <description>Intravenous, 1200 mg linezolid, single dose</description>
    <arm_group_label>Cohort 2: 1200 mg linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <description>Oral, 400 mg moxifloxacin, single dose</description>
    <arm_group_label>Cohort 2: 400 mg Moxifloxacin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects between the ages of 21 and 55 years.

          -  Body mass Index (BMI) of 18 to 30 kg/m2; and a total body weight &gt; 45 kg (99 lbs).

          -  An informed consent document signed and dated.

        Exclusion Criteria:

          -  Evidence or history of clinically significant abnormality.

          -  12-lead ECG demonstrating QTc &gt;450 msec at Screening.

          -  Receiving selective serotonin reuptake inhibitors (SSRIs) and/or sympathomimetic
             agents.

          -  Abnormal liver function tests.

          -  A positive urine drug screen, history of excessive alcohol and tobacco use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951151&amp;StudyName=A%20Study%20To%20Assess%20The%20Effect%20Of%20Linezolid%20On%20QTc%20Interval</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>March 2, 2010</results_first_submitted>
  <results_first_submitted_qc>May 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2010</results_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Linezolid, QTc interval, pharmacokinetics, therapeutic dose, supra-therapeutic dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Sequence 1</title>
          <description>Subjects were randomly assigned to placebo first, then linezolid 900 milligrams (mg) followed by 1200 mg linezolid, after a washout period of 48 hours between doses in Sequence 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Sequence 2</title>
          <description>Subjects were randomly assigned to linezolid 900 mg first, then placebo, followed by 1200 mg linezolid, after a washout period of 48 hours between doses in Sequence 2.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Sequence 3</title>
          <description>Subjects were randomly assigned to linezolid 900 mg first, then 1200 mg linezolid, followed by placebo after a washout period of 48 hours between doses in Sequence 3.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2: Sequence 1</title>
          <description>Subjects were randomly assigned to placebo, then moxifloxacin, followed by linezolid 600 mg and 1200 mg, after a washout period of 48 hours between doses in Sequence 1.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: Sequence 2</title>
          <description>Subjects were randomly assigned to linezolid 600 mg first, then linezolid 1200 mg followed by placebo and moxifloxacin, after a washout period of 48 hours between doses in Sequence 2.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Sequence 3</title>
          <description>Subjects were randomly assigned to linezolid 1200 mg first, then moxifloxacin 400 mg followed by linezolid 600 mg and placebo after a washout period of 48 hours between doses in Sequence 3.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 2: Sequence 4</title>
          <description>Subjects were randomly assigned to moxifloxacin 400 mg first, then placebo followed by linezolid 1200 mg and 600 mg linezolid after a washout period of 48 hours between doses in Sequence 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Placebo, Linezolid 900 mg and 1200 mg</title>
          <description>Subjects were randomly assigned to placebo followed by linezolid 900 mg then 1200 mg linezolid in Sequence 1; or, linezolid 900 mg then linezolid 1200 mg followed by placebo in Sequence 2; or, linezolid 900 mg then placebo followed by linezolid 1200 mg in Sequence 3. There was a washout period of 48 hours between doses.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Placebo, Linezolid 600 mg and 1200 mg, Moxifloxacin</title>
          <description>Subjects were randomly assigned to placebo first then moxifloxacin followed by linezolid 600 mg and 1200 mg linezolid last in Sequence 1; or linezolid 600 mg first then linezolid 1200 mg followed by placebo and moxifloxacin last in Sequence 2; or, linezolid 1200 mg first then moxifloxacin 400 mg followed by linezolid 600 mg and placebo last in Sequence 3; or, moxifloxacin 400 mg first then placebo followed by linezolid 1200 mg and 600 mg linezolid last in Sequence 4. There was a washout period of 48 hours between each dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
        <time_frame>From the time the subject had taken at least one dose of study treatment up to 5 weeks</time_frame>
        <population>Safety Analysis Set (SAS): All subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>600 milliliters (mL) saline as a constant rate intravenous (IV) infusion of 60 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 900 mg Linezolid</title>
            <description>450 mL Zyvox plus 150 mL saline as a constant rate IV infusion of 60 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: 1200 mg Linezolid</title>
            <description>600 mL Zyvox as a constant rate IV infusion of 60 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
          <population>Safety Analysis Set (SAS): All subjects who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf) and Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC Last)</title>
        <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
        <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf) and Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC Last)</title>
          <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
          <population>PK parameter analysis population</population>
          <units>microgram (ug)*hours (hr)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC inf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.49" spread="47.372"/>
                    <measurement group_id="O2" value="346.89" spread="77.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC last</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.26" spread="48.542"/>
                    <measurement group_id="O2" value="332.26" spread="71.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Maximum Observed Plasma Concentration (Cmax)</title>
          <population>PK parameter analysis population</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="3.681"/>
                    <measurement group_id="O2" value="29.37" spread="6.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.0" upper_limit="10.3"/>
                    <measurement group_id="O2" value="7.1" lower_limit="5.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Clearance of Linezolid (CL)</title>
        <description>Drug clearance = Dose / AUC inf</description>
        <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Clearance of Linezolid (CL)</title>
          <description>Drug clearance = Dose / AUC inf</description>
          <population>PK parameter analysis population</population>
          <units>mL/minute (min)/kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0173" spread="0.14637"/>
                    <measurement group_id="O2" value="0.8813" spread="0.16623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Steady-State Volume of Distribution (Vss)</title>
        <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
        <time_frame>predose, 30 minutes, and at 1 (end of infusion), 1.5, 2, 3, 4, 6, 8, 12, 24, and 46 hours after start of infusion</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Steady-State Volume of Distribution (Vss)</title>
          <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
          <population>PK parameter analysis population</population>
          <units>L/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6016" spread="0.06869"/>
                    <measurement group_id="O2" value="0.5776" spread="0.04605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2: Mean Time-Matched Difference in Time Corresponding to Beginning of Depolarization to Repolarization of the Ventricles, Corrected for Heart Rate Using Fridericia's Formula (QTcF Interval) Between Linezolid 600 mg and 1200 mg Compared to Placebo</title>
        <description>The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for ventricular rate (VR) using the QT and VR from each electrocardiogram by Fridericia’s formula (QTcF = QT divided by cube root of VR in seconds). A measure of dispersion is not available.</description>
        <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <population>The pharmacokinetic (PK) parameter analysis population was defined as all subjects randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
            <description>Zyvox IV Injection</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
            <description>Zyvox IV Injection</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
            <description>0.9% Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Mean Time-Matched Difference in Time Corresponding to Beginning of Depolarization to Repolarization of the Ventricles, Corrected for Heart Rate Using Fridericia's Formula (QTcF Interval) Between Linezolid 600 mg and 1200 mg Compared to Placebo</title>
          <description>The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for ventricular rate (VR) using the QT and VR from each electrocardiogram by Fridericia’s formula (QTcF = QT divided by cube root of VR in seconds). A measure of dispersion is not available.</description>
          <population>The pharmacokinetic (PK) parameter analysis population was defined as all subjects randomized and treated who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.</population>
          <units>milliseconds (msec)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.31"/>
                    <measurement group_id="O2" value="422.34"/>
                    <measurement group_id="O3" value="419.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.71"/>
                    <measurement group_id="O2" value="420.89"/>
                    <measurement group_id="O3" value="422.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.27"/>
                    <measurement group_id="O2" value="412.30"/>
                    <measurement group_id="O3" value="419.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.85"/>
                    <measurement group_id="O2" value="421.92"/>
                    <measurement group_id="O3" value="418.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.75"/>
                    <measurement group_id="O2" value="412.25"/>
                    <measurement group_id="O3" value="411.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.99"/>
                    <measurement group_id="O2" value="413.45"/>
                    <measurement group_id="O3" value="411.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.83"/>
                    <measurement group_id="O2" value="417.27"/>
                    <measurement group_id="O3" value="415.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 0.5 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 1 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 2 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-7.70</ci_lower_limit>
            <ci_upper_limit>-3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 4 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 8 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 12 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 24 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 0.5 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>4.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 1 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-3.95</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 2 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-9.68</ci_lower_limit>
            <ci_upper_limit>-5.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 4 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>5.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 8 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 12 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 24 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin and Placebo</title>
        <description>A measure of dispersion is not available.</description>
        <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Moxifloxacin</title>
            <description>Oral administration, positive control, not blinded.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin and Placebo</title>
          <description>A measure of dispersion is not available.</description>
          <population>PK parameter analysis population</population>
          <units>msec</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423.11"/>
                    <measurement group_id="O2" value="419.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.50"/>
                    <measurement group_id="O2" value="422.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.07"/>
                    <measurement group_id="O2" value="419.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.29"/>
                    <measurement group_id="O2" value="418.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420.53"/>
                    <measurement group_id="O2" value="411.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.02"/>
                    <measurement group_id="O2" value="411.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.99"/>
                    <measurement group_id="O2" value="415.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 0.5 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 1 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>4.66</ci_lower_limit>
            <ci_upper_limit>9.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 2 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>8.10</ci_lower_limit>
            <ci_upper_limit>12.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 4 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>7.67</ci_lower_limit>
            <ci_upper_limit>12.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 8 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>7.23</ci_lower_limit>
            <ci_upper_limit>11.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 12 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>4.87</ci_lower_limit>
            <ci_upper_limit>9.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 24 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>4.35</ci_lower_limit>
            <ci_upper_limit>8.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Mean Time-Matched Difference in Uncorrected QT Intervals Between Linezolid 600 mg and 1200 mg Compared to Placebo</title>
        <description>A measure of dispersion is not available.</description>
        <time_frame>0.5, 1, 2, 4, 8, 12, 24 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Placebo</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O3">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Mean Time-Matched Difference in Uncorrected QT Intervals Between Linezolid 600 mg and 1200 mg Compared to Placebo</title>
          <description>A measure of dispersion is not available.</description>
          <population>PK parameter analysis population</population>
          <units>msec</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.08"/>
                    <measurement group_id="O2" value="422.60"/>
                    <measurement group_id="O3" value="420.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.25"/>
                    <measurement group_id="O2" value="414.80"/>
                    <measurement group_id="O3" value="410.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.15"/>
                    <measurement group_id="O2" value="415.40"/>
                    <measurement group_id="O3" value="406.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420.58"/>
                    <measurement group_id="O2" value="419.66"/>
                    <measurement group_id="O3" value="418.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.30"/>
                    <measurement group_id="O2" value="399.66"/>
                    <measurement group_id="O3" value="406.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.85"/>
                    <measurement group_id="O2" value="396.56"/>
                    <measurement group_id="O3" value="398.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.38"/>
                    <measurement group_id="O2" value="415.80"/>
                    <measurement group_id="O3" value="419.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 0.5 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 1 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-11.51</ci_lower_limit>
            <ci_upper_limit>-3.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 2 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-9.81</ci_lower_limit>
            <ci_upper_limit>-1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 4 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-4.97</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 8 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-9.69</ci_lower_limit>
            <ci_upper_limit>-1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 12 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-6.34</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 24 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-4.64</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 0.5 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-7.54</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 1 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-16.24</ci_lower_limit>
            <ci_upper_limit>-8.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 2 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-18.44</ci_lower_limit>
            <ci_upper_limit>-10.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 4 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-6.24</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 8 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.95</ci_lower_limit>
            <ci_upper_limit>5.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 12 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-3.94</ci_lower_limit>
            <ci_upper_limit>4.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Inferential analysis at 24 hour post-dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>6.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: AUC Inf and AUC Last</title>
        <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
        <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 900 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: AUC Inf and AUC Last</title>
          <description>AUC inf = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.
AUC last = Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).</description>
          <population>PK parameter analysis population</population>
          <units>ug *hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC Inf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.75" spread="36.156"/>
                    <measurement group_id="O2" value="328.75" spread="79.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Last</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.52" spread="32.121"/>
                    <measurement group_id="O2" value="299.40" spread="62.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Cmax</title>
        <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Cmax</title>
          <population>PK parameter analysis population</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.06" spread="2.616"/>
                    <measurement group_id="O2" value="30.76" spread="4.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Tmax and t1/2</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Tmax is the time to reach Cmax.</description>
        <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Tmax and t1/2</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Tmax is the time to reach Cmax.</description>
          <population>PK parameter analysis population</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.083" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.095" lower_limit="2.83" upper_limit="10.40"/>
                    <measurement group_id="O2" value="6.796" lower_limit="3.12" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: CL</title>
        <description>Drug clearance = Dose / AUC inf</description>
        <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: CL</title>
          <description>Drug clearance = Dose / AUC inf</description>
          <population>PK parameter analysis population</population>
          <units>mL/min/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2825" spread="0.36529"/>
                    <measurement group_id="O2" value="1.1000" spread="0.27875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Vss</title>
        <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
        <time_frame>Predose, 30 minutes, 1, 2, 4, 8, 12 hours post-dose</time_frame>
        <population>PK parameter analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Vss</title>
          <description>Vss = (mean residence time [The average total time molecules of a given dose spend in the body] extrapolated to infinity) multiplied by CL</description>
          <population>PK parameter analysis population</population>
          <units>L/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6418" spread="0.08353"/>
                    <measurement group_id="O2" value="0.6185" spread="0.06560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Number of Subjects With AEs and SAEs</title>
        <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
        <time_frame>From the time the subject had taken at least one dose of study treatment up to 5 weeks</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: 600 mg Linezolid</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 1200 mg Linezolid</title>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo</title>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Number of Subjects With AEs and SAEs</title>
          <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product(s) were reported.</description>
          <population>SAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo</title>
        </group>
        <group group_id="E2">
          <title>Cohort 1: 900 mg Linezolid</title>
        </group>
        <group group_id="E3">
          <title>Cohort 1: 1200 mg Linezolid</title>
        </group>
        <group group_id="E4">
          <title>Cohort 2: Placebo</title>
        </group>
        <group group_id="E5">
          <title>Cohort 2: 600 mg Linezolid</title>
        </group>
        <group group_id="E6">
          <title>Cohort 2: 1200 mg Linezolid</title>
        </group>
        <group group_id="E7">
          <title>Cohort 2: 400 mg Moxifloxacin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

